Pediatrix Medical Group (NYSE:MD) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

Other equities research analysts have also issued research reports about the company. Truist Financial reduced their price target on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Monday. Mizuho increased their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Macquarie began coverage on shares of Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, UBS Group boosted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pediatrix Medical Group has a consensus rating of “Hold” and a consensus price target of $16.25.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock opened at $12.73 on Thursday. The business has a 50 day moving average of $14.35 and a 200-day moving average of $11.54. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a market capitalization of $1.09 billion, a P/E ratio of -4.16, a P/E/G ratio of 2.00 and a beta of 1.58.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $0.29 earnings per share. On average, equities research analysts predict that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Activity

In related news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP raised its stake in shares of Pediatrix Medical Group by 1.5% in the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after purchasing an additional 125,000 shares during the last quarter. State Street Corp raised its position in Pediatrix Medical Group by 1.4% in the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after buying an additional 50,597 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Pediatrix Medical Group by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after acquiring an additional 45,155 shares during the last quarter. Dana Investment Advisors Inc. grew its stake in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Finally, Weiss Asset Management LP raised its holdings in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after purchasing an additional 306,143 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.